Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis

DRAFT guidance does not recommend use of fedratinib as it was not considered a cost-effective use of NHS resources and it is unlikely that collecting more data in Cancer Drugs Fund would resolve uncertainties in the evidence.

Source:

National Institute for Health and Care Excellence